Analysts Set Biohaven Ltd. (NYSE:BHVN) PT at $25.93

Shares of Biohaven Ltd. (NYSE:BHVN) have been assigned an average recommendation of “Moderate Buy” from the eighteen brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $25.5714.

BHVN has been the subject of several recent analyst reports. Morgan Stanley reduced their target price on Biohaven from $26.00 to $21.00 and set an “overweight” rating for the company in a research report on Tuesday, January 6th. JPMorgan Chase & Co. cut their price objective on Biohaven from $47.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, November 20th. Royal Bank Of Canada decreased their price objective on shares of Biohaven from $19.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Thursday, November 6th. UBS Group lowered shares of Biohaven from a “buy” rating to a “neutral” rating and dropped their target price for the company from $26.00 to $11.00 in a research report on Wednesday, November 26th. Finally, BTIG Research reissued a “buy” rating and issued a $16.00 price target on shares of Biohaven in a research note on Tuesday, November 18th.

Insider Activity at Biohaven

In other news, Director John W. Childs acquired 3,333,333 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was purchased at an average cost of $7.50 per share, for a total transaction of $24,999,997.50. Following the acquisition, the director owned 5,653,904 shares of the company’s stock, valued at $42,404,280. This trade represents a 143.64% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO George C. Clark acquired 17,000 shares of Biohaven stock in a transaction dated Monday, November 17th. The shares were purchased at an average price of $8.52 per share, for a total transaction of $144,840.00. Following the completion of the transaction, the chief accounting officer directly owned 20,000 shares in the company, valued at approximately $170,400. The trade was a 566.67% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 4,416,999 shares of company stock valued at $33,144,833 over the last ninety days. 16.00% of the stock is currently owned by insiders.

Institutional Trading of Biohaven

Hedge funds have recently bought and sold shares of the company. Bellevue Group AG boosted its stake in Biohaven by 37.3% in the second quarter. Bellevue Group AG now owns 2,802,853 shares of the company’s stock worth $39,548,000 after buying an additional 762,000 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Biohaven by 31.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,572,042 shares of the company’s stock worth $36,292,000 after acquiring an additional 612,209 shares during the last quarter. Armistice Capital LLC boosted its stake in shares of Biohaven by 27.6% in the 2nd quarter. Armistice Capital LLC now owns 2,136,000 shares of the company’s stock valued at $30,139,000 after purchasing an additional 462,578 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Biohaven by 3.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,030,919 shares of the company’s stock valued at $28,660,000 after purchasing an additional 71,939 shares during the last quarter. Finally, Holocene Advisors LP raised its position in Biohaven by 19.1% in the 2nd quarter. Holocene Advisors LP now owns 1,495,641 shares of the company’s stock worth $21,103,000 after purchasing an additional 239,889 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Stock Performance

NYSE BHVN opened at $11.12 on Tuesday. The company’s 50 day simple moving average is $10.12 and its two-hundred day simple moving average is $13.32. The company has a debt-to-equity ratio of 1.91, a current ratio of 2.86 and a quick ratio of 2.86. Biohaven has a 1 year low of $7.48 and a 1 year high of $44.28. The stock has a market capitalization of $1.18 billion, a PE ratio of -1.46 and a beta of 1.14.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.64) EPS for the quarter, beating analysts’ consensus estimates of ($1.91) by $0.27. Analysts predict that Biohaven will post -8.9 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.